Ian Collins

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels
    Ian Collins
    Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, CM20 2QR, United Kingdom
    J Med Chem 45:1887-900. 2002
  2. ncbi Targeted small-molecule inhibitors of protein kinase B as anticancer agents
    Ian Collins
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Surrey SM2 5NG, UK
    Anticancer Agents Med Chem 9:32-50. 2009
  3. ncbi Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B
    Ian Collins
    Cancer Research, UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey
    Bioorg Med Chem 14:1255-73. 2006
  4. ncbi New approaches to molecular cancer therapeutics
    Ian Collins
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nat Chem Biol 2:689-700. 2006
  5. ncbi Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)
    Tatiana McHardy
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Med Chem 53:2239-49. 2010
  6. ncbi Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
    Timothy A Yap
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Mol Cancer Ther 10:360-71. 2011
  7. ncbi CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors
    Victoria E Anderson
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 71:463-72. 2011
  8. ncbi Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
    Thomas P Matthews
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Bioorg Med Chem Lett 20:4045-9. 2010
  9. ncbi Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
    John C Reader
    Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    J Med Chem 54:8328-42. 2011
  10. ncbi Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2
    John J Caldwell
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    J Med Chem 54:580-90. 2011

Collaborators

Detail Information

Publications34

  1. ncbi 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional delectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels
    Ian Collins
    Merck Sharp and Dohme Research Laboratories, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, CM20 2QR, United Kingdom
    J Med Chem 45:1887-900. 2002
    ....
  2. ncbi Targeted small-molecule inhibitors of protein kinase B as anticancer agents
    Ian Collins
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Surrey SM2 5NG, UK
    Anticancer Agents Med Chem 9:32-50. 2009
    ....
  3. ncbi Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B
    Ian Collins
    Cancer Research, UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey
    Bioorg Med Chem 14:1255-73. 2006
    ..Potent PKB inhibitors from this series inhibited GSK3beta phosphorylation in cellular assays, consistent with inhibition of PKB kinase activity in cells...
  4. ncbi New approaches to molecular cancer therapeutics
    Ian Collins
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Nat Chem Biol 2:689-700. 2006
    ..We show how chemical biology approaches offer techniques for interconnecting elements of the traditional linear progression from gene to drug, thereby providing a basis for increasing speed and success in cancer drug discovery...
  5. ncbi Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt)
    Tatiana McHardy
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    J Med Chem 53:2239-49. 2010
    ..Representative compounds modulated biomarkers of signaling through PKB in vivo and strongly inhibited the growth of human tumor xenografts in nude mice at well-tolerated doses...
  6. ncbi Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930
    Timothy A Yap
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Mol Cancer Ther 10:360-71. 2011
    ..We have also developed a novel biomarker assay for the inhibition of AKT in human hair follicles, which is currently being used in clinical trials...
  7. ncbi CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors
    Victoria E Anderson
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 71:463-72. 2011
    ..Consequently, our findings imply that CHK2 inhibitors may exert therapeutic activity in combination with PARP inhibitors...
  8. ncbi Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
    Thomas P Matthews
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Bioorg Med Chem Lett 20:4045-9. 2010
    ..These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold...
  9. ncbi Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing
    John C Reader
    Cancer Research UK Cancer Therapeutics Unit and Division of Structural Biology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    J Med Chem 54:8328-42. 2011
    ..A potent and highly selective isoquinoline CHK1 inhibitor (SAR-020106) was identified, which potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice...
  10. ncbi Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2
    John J Caldwell
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    J Med Chem 54:580-90. 2011
    ..In addition to showing mechanistic inhibition of CHK2 in HT29 human colon cancer cells, a concentration dependent radioprotective effect in mouse thymocytes was demonstrated for the potent inhibitor 46 (CCT241533)...
  11. ncbi Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2
    Stephen Hilton
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    Bioorg Med Chem 18:707-18. 2010
    ..Compounds from this series showed activity in cell-based mechanistic assays for inhibition of CHK2...
  12. ncbi Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration
    John J Caldwell
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, U K
    J Med Chem 51:2147-57. 2008
    ..Selectivity for PKB vs PKA was observed with 4-aminopiperidine derivatives, and the most PKB-selective inhibitor (30-fold) showed significantly different bound conformations between PKA and PKA-PKB chimera...
  13. ncbi Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization
    Daniel K Whelligan
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    J Med Chem 53:7682-98. 2010
    ..The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2...
  14. ncbi The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
    Michael I Walton
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Surrey, United Kingdom
    Mol Cancer Ther 9:89-100. 2010
    ..SAR-020106 represents a novel class of CHK1 inhibitors that can enhance antitumor activity with selected anticancer drugs in vivo and may therefore have clinical utility...
  15. ncbi Anticancer therapy with checkpoint inhibitors: what, where and when?
    Michelle D Garrett
    Cancer Research UK Cancer Therapeutics Unit, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton SM25NG, UK
    Trends Pharmacol Sci 32:308-16. 2011
    ..g. poly(ADP-ribose) polymerase inhibitors]. We also consider the single-agent activity of checkpoint kinase inhibitors for tumours with defined genetic backgrounds...
  16. ncbi Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin
    Lynette A Smyth
    Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Belmont, Surrey SM2 5NG, UK
    Bioorg Med Chem 19:3569-78. 2011
    ....
  17. ncbi Identification of small-molecule inhibitors of protein kinase B (PKB/AKT) in an AlphaScreenTM high-throughput screen
    Samantha Burns
    Cancer Research UK Centre for Cancer Therapeutics, Haddow Laboratories, The Institute of Cancer Research, Belmont, Sutton, UK
    J Biomol Screen 11:822-7. 2006
    ..01% Triton X100. The authors now include an interference assay during hit confirmation procedures and check compound activity in the presence of Triton X100 in an attempt to eliminate nonspecific aggregators at an early stage...
  18. ncbi Fragment-based discovery of inhibitors of protein kinase B
    Thomas G Davies
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
    Curr Top Med Chem 9:1705-17. 2009
    ..Compounds with selectivity for PKB over PKA and other kinases were identified by this approach, resulting in potent inhibitors with in vivo activity through both oral and systemic administration, and suitable for further development...
  19. ncbi Identification of inhibitors of checkpoint kinase 1 through template screening
    Thomas P Matthews
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK
    J Med Chem 52:4810-9. 2009
    ....
  20. ncbi Checkpoint kinase inhibitors: a patent review (2009 - 2010)
    Michael Lainchbury
    The Institute of Cancer Research, Cancer Research UK Cancer Therapeutics Unit, Haddow Laboratories, Sutton, Surrey, UK
    Expert Opin Ther Pat 21:1191-210. 2011
    ..The level of newly published patent applications covering CHK1 and CHK2 inhibitors remains high and a diverse range of scaffolds has been claimed...
  21. ncbi Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors
    Ian Collins
    Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, 15 Cotswold Road, Sutton SM2 5NG, UK
    Curr Opin Pharmacol 5:366-73. 2005
    ....
  22. ncbi Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response
    Maruf M U Ali
    Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, London, UK
    EMBO J 30:894-905. 2011
    ..These studies identify human Ire1? as a target for development of ATP-competitive inhibitors that will modulate the UPR in human cells, which has particular relevance for myeloma and other secretory malignancies...
  23. ncbi Measuring and interpreting the selectivity of protein kinase inhibitors
    Lynette A Smyth
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    J Chem Biol 2:131-51. 2009
    ..Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors...
  24. ncbi Probing the probes: fitness factors for small molecule tools
    Paul Workman
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
    Chem Biol 17:561-77. 2010
    ....
  25. ncbi Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors
    Noan-Minh Chau
    Cell Growth Regulation and Angiogenesis Team, Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 65:4918-28. 2005
    ..Our cell-based assay approach has successfully identified novel compounds that differentially target hypoxia and/or growth factor-mediated induction of HIF-1alpha...
  26. ncbi CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
    Laurent Antoni
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Rev Cancer 7:925-36. 2007
    ....
  27. ncbi A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation
    Anthea Hardcastle
    Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, United Kingdom
    Mol Cancer Ther 6:1112-22. 2007
    ..In the acetylation arm, two compounds increased cellular acetylation, one of which inhibited histone deacetylase activity. A third compound decreased cellular histone acetylation, potentially through a novel mechanism of action...
  28. ncbi Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design
    Alastair Donald
    J Med Chem 50:2289-92. 2007
    ..An elaborated lead compound showed cell growth inhibition and effects on cellular signaling pathways characteristic of PKB inhibition...
  29. ncbi 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer
    Paul A Brough
    Vernalis Ltd, Granta Park, Great Abington, Cambridge CB21 6GB, U K p brough vernalis com
    J Med Chem 51:196-218. 2008
    ..Compound 40f is retained in tumors in vivo when administered i.p., as evaluated by cassette dosing in tumor-bearing mice. In a human colon cancer xenograft model, 40f inhibits tumor growth by approximately 50%...
  30. ncbi The Claisen rearrangement approach to fused bicyclic medium-ring oxacycles
    Jonathan W Burton
    Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UKCB2 1EW
    Org Biomol Chem 6:693-702. 2008
    ..The synthesis of five fused-bicyclic medium-ring lactones carrying identical ring-fusion to that in the polyether toxins is described using an enolate hydroxylation, intramolecular hydrosilation, Claisen rearrangement sequence...
  31. ncbi A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera
    Thomas G Davies
    Astex Therapeutics Ltd, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK
    J Mol Biol 367:882-94. 2007
    ..We provide a structural explanation for this difference, and highlight the ability of PKA-PKB to mimic the true PKB binding mode in this case...
  32. ncbi Identification of novel keratinocyte differentiation modulating compounds by high-throughput screening
    Masaru Honma
    Keratinocyte Laboratory, Cancer Research UK London Research Institute, London
    J Biomol Screen 11:977-84. 2006
    ..Because the compound affected the tumor cells at a lower concentration than primary keratinocytes, it may have potential as an antitumor therapy...
  33. ncbi An inhibitor of FtsZ with potent and selective anti-staphylococcal activity
    David J Haydon
    Prolysis, Begbroke Science Park, Oxfordshire OX5 1PF, UK
    Science 321:1673-5. 2008
    ..aureus. The data validate FtsZ as a target for antibacterial intervention and identify PC190723 as suitable for optimization into a new anti-staphylococcal therapy...
  34. ncbi Investigation of conjugate addition/intramolecular nitrone dipolar cycloadditions and their use in the synthesis of dendrobatid alkaloid precursors
    Helen T Horsley
    Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK CB2 1EW
    Org Biomol Chem 2:1258-65. 2004
    ..Conditions have been developed for the two-step conversion of the ketone 12 under thermodynamic control into the racemic tricyclic 6,6,5-adduct 16 which is the core precursor of all the known histrionicotoxin alkaloids...